Loading company…
NexCure develops outpatient centers for delivering CAR-T and other advanced cancer therapies.
NexCure develops outpatient treatment centers specializing in CAR-T and T-cell engager therapies, supported by patient selection, remote monitoring and clinical protocols. It works with US health systems to improve access to these treatments. Founded in 2024 and based in Boston, the company raised USD 19.00 mn in Series A funding in March 2026, led by RA Capital, with participation from Cencora Ventures and Oncology Ventures.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in